LMP

LMP is a preclinical-stage drug candidate developed by IGC Pharma (formerly India Globalization Capital) that utilizes a proprietary Leukotriene Modifying Platform to target neuroinflammation. Neuroinflammation is a critical pathological driver in the progression of neurodegenerative diseases, most notably Alzheimer's disease. LMP is designed to modulate the leukotriene signaling pathway, which is responsible for mediating inflammatory responses in the central nervous system. By inhibiting or modifying the activity of leukotrienes, the drug aims to reduce the inflammatory cascade, potentially providing neuroprotective benefits and slowing cognitive decline. It is currently being positioned as a potential treatment for neuroinflammation associated with Alzheimer's and other CNS disorders.

Other names

Leukotriene Modifying Platform